Overview

ACZ885 for the Treatment of Abdominal Aortic Aneurysm

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA). The purpose of the study was to provide data to enable decisions regarding the further development of ACZ885 for subjects with abdominal aortic aneurysms. The design of this study addressed the primary objective of evaluating the change in aneurysmal size in subjects with AAA as a result of treatment with ACZ885.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals